Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

xylem inc. - XYL

XYL

Close Chg Chg %
138.73 0.02 0.01%

Closed Market

138.75

+0.02 (0.01%)

Volume: 484.74K

Last Updated:

Dec 26, 2025, 3:59 PM EDT

Trade Now

Company Overview: xylem inc. - XYL

XYL Key Data

Open

$138.66

 Day Range

138.18 - 139.13

52 Week Range

100.47 - 154.24

 Market Cap

$33.78B

Shares Outstanding

243.47M

 Public Float

242.83M

Beta

1.17

 Rev. Per Employee

N/A

P/E Ratio

35.69

 EPS

$3.90

Yield

115.33%

 Dividend

$0.40

EX-DIVIDEND DATE

Nov 25, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.26M

  

XYL Performance

1 Week
 
 0.53%
 
1 Month
 
 -1.33%
 
3 Months
 
 -2.96%
 
1 Year
 
 18.10%
 
5 Years
 
 38.45%
 

XYL Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 24
Full Ratings ➔

About xylem inc. - XYL

Xylem, Inc. engages in the design, manufacture, and application of engineered technologies for the water industry. It operates through the following business segments: Water Infrastructure, Applied Water, and Measurement and Control Solutions. The Water Infrastructure segment focuses on the transportation, treatment and testing of water. The Applied Water segment encompasses the uses of water and focuses on the commercial, residential, and industrial end markets. The Measurement and Control Solutions segment focuses on developing technology solutions that enable intelligent use and conservation of critical water and energy resources as well as analytical instrumentation used in the testing of water. The company was founded in 2011 and is headquartered in Washington, DC.

XYL At a Glance

Xylem, Inc.
301 Water Street SE
Washington, District of Columbia 20003
Phone 1-202-869-9150 Revenue 8.56B
Industry Industrial Machinery Net Income 890.00M
Sector Producer Manufacturing 2024 Sales Growth 16.235%
Fiscal Year-end 12 / 2025 Employees 23,000
View SEC Filings

XYL Valuation

P/E Current 35.69
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 31.745
Price to Sales Ratio 3.299
Price to Book Ratio 2.649
Price to Cash Flow Ratio 22.37
Enterprise Value to EBITDA 18.189
Enterprise Value to Sales 3.473
Total Debt to Enterprise Value 0.08

XYL Efficiency

Revenue/Employee 372,304.348
Income Per Employee 38,695.652
Receivables Turnover 5.134
Total Asset Turnover 0.525

XYL Liquidity

Current Ratio 1.754
Quick Ratio 1.328
Cash Ratio 0.48

XYL Profitability

Gross Margin 37.534
Operating Margin 12.531
Pretax Margin 12.694
Net Margin 10.394
Return on Assets 5.459
Return on Equity 8.554
Return on Total Capital 6.841
Return on Invested Capital 6.962

XYL Capital Structure

Total Debt to Total Equity 22.242
Total Debt to Total Capital 18.195
Total Debt to Total Assets 14.352
Long-Term Debt to Equity 20.861
Long-Term Debt to Total Capital 17.065
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Xylem Inc. - XYL

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
5.20B 5.54B 7.37B 8.56B
Sales Growth
+6.71% +6.58% +32.95% +16.23%
Cost of Goods Sold (COGS) incl D&A
3.22B 3.44B 4.64B 5.35B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
245.00M 236.00M 436.00M 562.00M
Depreciation
118.00M 111.00M 193.00M 258.00M
Amortization of Intangibles
127.00M 125.00M 243.00M 304.00M
COGS Growth
+5.75% +6.71% +35.13% +15.21%
Gross Income
1.98B 2.10B 2.72B 3.21B
Gross Income Growth
+8.32% +6.37% +29.41% +17.99%
Gross Profit Margin
+38.07% +37.99% +36.98% +37.53%
2021 2022 2023 2024 5-year trend
SG&A Expense
1.38B 1.44B 1.99B 2.14B
Research & Development
204.00M 206.00M 232.00M 230.00M
Other SG&A
1.18B 1.23B 1.76B 1.91B
SGA Growth
+3.98% +4.12% +38.13% +7.64%
Other Operating Expense
- - - -
-
Unusual Expense
(14.00M) 140.00M 46.00M 30.00M
EBIT after Unusual Expense
610.00M 525.00M 689.00M 1.04B
Non Operating Income/Expense
(2.00M) (6.00M) 25.00M 120.00M
Non-Operating Interest Income
7.00M 16.00M 28.00M 28.00M
Equity in Earnings of Affiliates
- - 9.00M (4.00M)
-
Interest Expense
97.00M 79.00M 79.00M 76.00M
Interest Expense Growth
- +1.04% -18.56% -3.80%
Gross Interest Expense
97.00M 79.00M 79.00M 76.00M
Interest Capitalized
- - - -
-
Pretax Income
511.00M 440.00M 635.00M 1.09B
Pretax Income Growth
+79.30% -13.89% +44.32% +71.18%
Pretax Margin
+9.83% +7.94% +8.62% +12.69%
Income Tax
84.00M 85.00M 26.00M 197.00M
Income Tax - Current - Domestic
21.00M 93.00M 19.00M 143.00M
Income Tax - Current - Foreign
53.00M 56.00M 86.00M 90.00M
Income Tax - Deferred - Domestic
(2.00M) (55.00M) (57.00M) (49.00M)
Income Tax - Deferred - Foreign
12.00M (9.00M) (22.00M) 13.00M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - 9.00M (4.00M)
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
427.00M 355.00M 609.00M 890.00M
Minority Interest Expense
- - - -
-
Net Income
427.00M 355.00M 609.00M 890.00M
Net Income Growth
+68.11% -16.86% +71.55% +46.14%
Net Margin Growth
+8.21% +6.41% +8.27% +10.39%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
427.00M 355.00M 609.00M 890.00M
Preferred Dividends
- - - -
-
Net Income Available to Common
427.00M 355.00M 609.00M 890.00M
EPS (Basic)
2.369 1.9698 2.8063 3.6688
EPS (Basic) Growth
+67.99% -16.85% +42.47% +30.73%
Basic Shares Outstanding
180.25M 180.22M 217.01M 242.58M
EPS (Diluted)
2.3523 1.9616 2.7913 3.6547
EPS (Diluted) Growth
+67.71% -16.61% +42.30% +30.93%
Diluted Shares Outstanding
181.53M 180.98M 218.18M 243.52M
EBITDA
841.00M 901.00M 1.17B 1.64B
EBITDA Growth
+12.43% +7.13% +29.97% +39.62%
EBITDA Margin
+16.18% +16.26% +15.90% +19.09%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 170.50
Number of Ratings 24 Current Quarters Estimate 1.411
FY Report Date 12 / 2025 Current Year's Estimate 5.061
Last Quarter’s Earnings 1.37 Median PE on CY Estimate N/A
Year Ago Earnings 4.27 Next Fiscal Year Estimate 5.568
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 18 13 20 20
Mean Estimate 1.41 1.16 5.06 5.57
High Estimates 1.45 1.25 5.09 5.72
Low Estimate 1.39 1.05 5.04 5.36
Coefficient of Variance 1.31 5.27 0.27 1.65

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 13 13 13
OVERWEIGHT 3 4 3
HOLD 8 7 8
UNDERWEIGHT 0 1 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Xylem Inc. - XYL

Date Name Shares Transaction Value
Mar 12, 2025 Matthew F. Pine Pres. & CEO; Director 24,192 Bona fide gift Non-derivative transaction at $123.63 per share 2,990,856.96
Mar 11, 2025 Claudia S. Toussaint SVP, CPSO 3,939 Bona fide gift Non-derivative transaction at $129.78 per share 511,203.42
Mar 7, 2025 Dorothy G. Capers SVP & General Counsel 8,015 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $127.26 per share 1,019,988.90
Mar 7, 2025 Meredith Emmerich SVP & Pres, AW 3,721 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 7, 2025 Albert H. Cho SVP, Strategy 13,970 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $129.67 per share 1,811,489.90
Mar 7, 2025 Matthew F. Pine Pres. & CEO; Director 49,392 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 7, 2025 Geri McShane VP, Controller & CAO 1,861 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 7, 2025 Geri McShane VP, Controller & CAO 4,950 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $129.67 per share 641,866.50
Mar 7, 2025 Dorothy G. Capers SVP & General Counsel 4,905 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 7, 2025 Dorothy G. Capers SVP & General Counsel N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 7, 2025 Dorothy G. Capers SVP & General Counsel 2,079 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 7, 2025 Dorothy G. Capers SVP & General Counsel 9,413 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $129.67 per share 1,220,583.71
Mar 7, 2025 Dorothy G. Capers SVP & General Counsel 20,041 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $101.09 per share 2,025,944.69
Mar 7, 2025 Dorothy G. Capers SVP & General Counsel 15,883 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $86.76 per share 1,378,009.08
Mar 7, 2025 William K. Grogan SVP & Chief Financial Officer 15,223 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 7, 2025 William K. Grogan SVP & Chief Financial Officer 32,415 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $129.67 per share 4,203,253.05
Mar 7, 2025 Hayati Yarkadas SVP & President, WI 8,119 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 7, 2025 Hayati Yarkadas SVP & President, WI 19,616 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $129.67 per share 2,543,606.72
Mar 7, 2025 Rodney O. Aulick SVP & President, WSS 5,751 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 7, 2025 Rodney O. Aulick SVP & President, WSS 75,774 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $129.67 per share 9,825,614.58

Xylem Inc. in the News